Table 2 Characteristics of the overall study population
Controls N = 52 | Patients N = 36 | |||
|---|---|---|---|---|
n | n | |||
Age, years (Media ± SD) | 49 | 33.71 ± 1.55 | 36 | 45.56 ± 2.21 * |
Gender (%) Male Female | 43 9 | 82.69 17.30 | 35 1 | 97.22 2.77 |
Gout onset time/Age (years) | NA | NA | 29 | 8.6, 37.02 |
gout flare (%) Chronic Gout (%) | NA NA | NA NA | 7 29 | 19.44 80.56 |
Normal weight (%) | 30 | 56.6 | 8 | 23.5* |
Overweight (%) | 19 | 35.8 | 14 | 41.2 |
Obesity (%) | 4 | 7.4 | 12 | 35.3* |
Hypertensión (%) | 1 | 2.17 | 8 | 22.22* |
Metabolic syndrome (%) | 0 | 0 | 11 | 29.7* |
Presence of tophi (%) | NA | NA | 10 | 27.8 |
Renal disease (%) | NA | NA | 4 | 10.8 |
Diabetes mellitus (%) | 0 | 0 | 0 | 0 |
Alcohol consumption(%) Yes No | ||||
17 | 33.3 | 14 | 42.4 | |
34 | 66.07 | 19 | 57.6 | |
Smoking (%) Smoker Non smoker Ex smoker | ||||
6 | 11.5 | 10 | 27* | |
40 | 76.9 | 18 | 48.6* | |
6 | 11.5 | 9 | 24.3 | |
Gout background in the family (%) Yes No | ||||
4 | 8.2 | 16 | 45.7* | |
45 | 91.8 | 19 | 54.3* | |
Medications | ||||
allopurinol | NA | NA | 7 | 19.44 |
aspirin | NA | NA | 2 | 5.55 |
colchicine | NA | NA | 3 | 8.33 |
hydrochlorothiazide | NA | NA | 2 | 5.55 |
bezafibrate | NA | NA | 1 | 2.77 |
Losartan | NA | NA | 1 | 2.77 |
prednisone | NA | NA | 1 | 2.77 |
indomethacin | NA | NA | 1 | 2.77 |
metoprolol | NA | NA | 1 | 2.77 |